Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. more
Time Frame | CCCC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.82% | -2.12% | -3% |
1-Month Return | -2.47% | -3.42% | -0.73% |
3-Month Return | -37.8% | -11.13% | 2.87% |
6-Month Return | -2.47% | -5.74% | 7.17% |
1-Year Return | -9.2% | 3.97% | 25.31% |
3-Year Return | -87.46% | 1.05% | 28.38% |
5-Year Return | -84.5% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 21.38M | 33.20M | 45.78M | 31.10M | 20.76M | [{"date":"2019-12-31","value":46.7,"profit":true},{"date":"2020-12-31","value":72.5,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.92,"profit":true},{"date":"2023-12-31","value":45.33,"profit":true}] |
Cost of Revenue | 47.66M | 77.47M | 2.91M | 7.57M | 117.71M | [{"date":"2019-12-31","value":40.49,"profit":true},{"date":"2020-12-31","value":65.81,"profit":true},{"date":"2021-12-31","value":2.47,"profit":true},{"date":"2022-12-31","value":6.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (26.28M) | (44.27M) | 42.88M | 23.52M | (96.95M) | [{"date":"2019-12-31","value":-61.3,"profit":false},{"date":"2020-12-31","value":-103.25,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":54.86,"profit":true},{"date":"2023-12-31","value":-226.11,"profit":false}] |
Gross Margin | (122.93%) | (133.37%) | 93.65% | 75.65% | (467.09%) | [{"date":"2019-12-31","value":-131.26,"profit":false},{"date":"2020-12-31","value":-142.41,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":80.78,"profit":true},{"date":"2023-12-31","value":-498.76,"profit":false}] |
Operating Expenses | 56.83M | 93.64M | 127.92M | 160.63M | 159.79M | [{"date":"2019-12-31","value":35.38,"profit":true},{"date":"2020-12-31","value":58.3,"profit":true},{"date":"2021-12-31","value":79.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.48,"profit":true}] |
Operating Income | (35.45M) | (60.45M) | (82.13M) | (129.53M) | (139.03M) | [{"date":"2019-12-31","value":-3545200000,"profit":false},{"date":"2020-12-31","value":-6044900000,"profit":false},{"date":"2021-12-31","value":-8213400000,"profit":false},{"date":"2022-12-31","value":-12953400000,"profit":false},{"date":"2023-12-31","value":-13903100000,"profit":false}] |
Total Non-Operating Income/Expense | 3.99M | (7.35M) | (3.52M) | 2.72M | 14.41M | [{"date":"2019-12-31","value":27.67,"profit":true},{"date":"2020-12-31","value":-50.97,"profit":false},{"date":"2021-12-31","value":-24.39,"profit":false},{"date":"2022-12-31","value":18.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (33.30M) | (66.96M) | (83.89M) | (128.18M) | (131.21M) | [{"date":"2019-12-31","value":-3329500000,"profit":false},{"date":"2020-12-31","value":-6696100000,"profit":false},{"date":"2021-12-31","value":-8389200000,"profit":false},{"date":"2022-12-31","value":-12817500000,"profit":false},{"date":"2023-12-31","value":-13121300000,"profit":false}] |
Income Taxes | 804.00K | (626.00K) | 2.15M | (1.68M) | 1.28M | [{"date":"2019-12-31","value":37.48,"profit":true},{"date":"2020-12-31","value":-29.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-78.14,"profit":false},{"date":"2023-12-31","value":59.67,"profit":true}] |
Income After Taxes | (34.10M) | (66.33M) | (86.04M) | (126.50M) | (132.49M) | [{"date":"2019-12-31","value":-3409900000,"profit":false},{"date":"2020-12-31","value":-6633500000,"profit":false},{"date":"2021-12-31","value":-8603700000,"profit":false},{"date":"2022-12-31","value":-12649900000,"profit":false},{"date":"2023-12-31","value":-13249300000,"profit":false}] |
Income From Continuous Operations | (34.10M) | (66.33M) | (83.89M) | (128.18M) | (134.92M) | [{"date":"2019-12-31","value":-3409900000,"profit":false},{"date":"2020-12-31","value":-6633500000,"profit":false},{"date":"2021-12-31","value":-8389200000,"profit":false},{"date":"2022-12-31","value":-12817500000,"profit":false},{"date":"2023-12-31","value":-13492400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (34.10M) | (66.33M) | (86.04M) | (126.50M) | (132.49M) | [{"date":"2019-12-31","value":-3409900000,"profit":false},{"date":"2020-12-31","value":-6633500000,"profit":false},{"date":"2021-12-31","value":-8603700000,"profit":false},{"date":"2022-12-31","value":-12649900000,"profit":false},{"date":"2023-12-31","value":-13249300000,"profit":false}] |
EPS (Diluted) | - | (17.69) | (1.82) | (2.63) | (2.66) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1769,"profit":false},{"date":"2021-12-31","value":-182,"profit":false},{"date":"2022-12-31","value":-263,"profit":false},{"date":"2023-12-31","value":-266,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CCCC | |
---|---|
Cash Ratio | 5.90 |
Current Ratio | 6.31 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CCCC | |
---|---|
ROA (LTM) | -20.61% |
ROE (LTM) | -46.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CCCC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.35 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.65 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CCCC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.28 |
P/B | 1.12 |
Price/FCF | NM |
EV/R | 2.46 |
EV/Ebitda | NM |
C4 Therapeutics Inc (CCCC) share price today is $3.95
Yes, Indians can buy shares of C4 Therapeutics Inc (CCCC) on Vested. To buy C4 Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CCCC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of C4 Therapeutics Inc (CCCC) via the Vested app. You can start investing in C4 Therapeutics Inc (CCCC) with a minimum investment of $1.
You can invest in shares of C4 Therapeutics Inc (CCCC) via Vested in three simple steps:
The 52-week high price of C4 Therapeutics Inc (CCCC) is $11.88. The 52-week low price of C4 Therapeutics Inc (CCCC) is $3.61.
The price-to-earnings (P/E) ratio of C4 Therapeutics Inc (CCCC) is
The price-to-book (P/B) ratio of C4 Therapeutics Inc (CCCC) is 1.12
The dividend yield of C4 Therapeutics Inc (CCCC) is 0.00%
The market capitalization of C4 Therapeutics Inc (CCCC) is $271.41M
The stock symbol (or ticker) of C4 Therapeutics Inc is CCCC